Silent atrial fibrillation (AF) is an asymptomatic atrial arrhythmia that can be diagnosed by chance during a systematic electrocardiogram, an external Holter, or from implanted cardiac devices. There is a significant body of the literature around silent AF, yet it remains largely underdiagnosed in everyday clinical practice. Meanwhile, new diagnostic tools have significantly improved the detection of silent AF, creating a potential for mass screening via new technologies and the promise of a major step forward in e-health progress. However, it is not yet known whether silent AF is associated with the same thromboembolic risk as symptomatic AF, and whether these asymptomatic and often short-lasting episodes therefore require anticoagulation therapy and rhythm management.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Dilaveris PE, Kennedy HL. Silent atrial fibrillation: epidemiology, diagnosis, and clinical impact. Clin. Cardiol. 40(6), 413–418 (2017).
MedlineGoogle Scholar
2. Kennedy HL. Silent atrial fibrillation: definition, clarification, and unanswered issues. Ann. Noninvasive Electrocardiol. 20(6), 518–525 (2015).
MedlineGoogle Scholar
3. Barbarossa A, Guerra F, Capucci A. Silent atrial fibrillation: a critical review. J. Atr. Fibrillation 7(3), 1138 (2014).
MedlineGoogle Scholar
4. Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC)Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESCEndorsed by the European Stroke Organisation (ESO). Eur. Heart J. 37, 2893–2962 (2016). • European guidelines on atrial fibrillation (AF) management.
MedlineGoogle Scholar
5. Guenancia C, Binquet C, Laurent G et al. Incidence and predictors of new-onset atrial fibrillation in septic shock patients in a medical ICU: data from 7-day Holter ECG monitoring. PLoS ONE 10(5), e0127168 (2015).
MedlineGoogle Scholar
6. Guenancia C, Pujos C, Debomy F, Malapert G, Laurent G, Bouchot O. Incidence and predictors of new-onset silent atrial fibrillation after coronary artery bypass graft surgery. Biomed. Res. Int. 2015, 703685 (2015).
MedlineGoogle Scholar
7. Witkowski M, Bissinger A, Grycewicz T, Lubinski A. Asymptomatic atrial fibrillation in patients with atrial fibrillation and implanted pacemaker. Int. J. Cardiol. 227, 583–588 (2017).
MedlineGoogle Scholar
8. Calenda BW, Fuster V, Halperin JL, Granger CB. Stroke risk assessment in atrial fibrillation: risk factors and markers of atrial myopathy. Nat. Rev. Cardiol. 13(9), 549–559 (2016). •• Major review on atrial cardiopathy and stroke risk.
Medline CASGoogle Scholar
9. Kamel H, Okin PM, Elkind MS, Iadecola C. Atrial fibrillation and mechanisms of stroke: time for a new model. Stroke 47(3), 895–900 (2016).
MedlineGoogle Scholar
10. Lowres N, Neubeck L, Redfern J, Freedman SB. Screening to identify unknown atrial fibrillation. A systematic review. Thromb. Haemost. 110(2), 213–222 (2013).
Medline CASGoogle Scholar
11. Fitzmaurice DA, Hobbs FD, Jowett S et al. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. BMJ 335(7616), 383 (2007).
MedlineGoogle Scholar
12. Hobbs FD, Fitzmaurice DA, Mant J et al. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol. Assess. 9(40), 1–74 (2005).
Google Scholar
13. Hindricks G, Pokushalov E, Urban L et al. Performance of a new leadless implantable cardiac monitor in detecting and quantifying atrial fibrillation: results of the XPECT trial. Circ. Arrhythm. Electrophysiol. 3(2), 141–147 (2010).
MedlineGoogle Scholar
14. Brambatti M, Connolly SJ, Gold MR et al. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation 129(21), 2094–2099 (2014).
MedlineGoogle Scholar
15. Orlov MV, Ghali JK, Araghi-Niknam M et al. Asymptomatic atrial fibrillation in pacemaker recipients: incidence, progression, and determinants based on the atrial high rate trial. Pacing Clin. Electrophysiol. 30(3), 404–411 (2007).
MedlineGoogle Scholar
16. Boriani G, Glotzer TV, Santini M et al. Device-detected atrial fibrillation and risk for stroke: an analysis of >10,000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices). Eur. Heart J. 35(8), 508–516 (2014).
MedlineGoogle Scholar
17. Glotzer TV, Hellkamp AS, Zimmerman J et al. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation 107(12), 1614–1619 (2003).
MedlineGoogle Scholar
18. Lorenzoni G, Folino F, Soriani N, Iliceto S, Gregori D. Cost-effectiveness of early detection of atrial fibrillation via remote control of implanted devices. J. Eval. Clin. Pract. 20(5), 570–577 (2014).
MedlineGoogle Scholar
19. Freedman B, Camm J, Calkins H et al. Screening for atrial fibrillation: a report of the AF-SCREEN International Collaboration. Circulation 135(19), 1851–1867 (2017).
MedlineGoogle Scholar
20. Perez MV, Mahaffey KW, Hedlin H et al. Large-scale assessment of a smartwatch to identify atrial fibrillation. N. Engl. J. Med. 381(20), 1909–1917 (2019). • Proof-of-concept of a smartwatch-based AF screening in the general population.
MedlineGoogle Scholar
21. Lowres N, Neubeck L, Salkeld G et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. Thromb. Haemost. 111(6), 1167–1176 (2014).
Medline CASGoogle Scholar
22. Lahdenoja O, Hurnanen T, Iftikhar Z et al. Atrial fibrillation detection via accelerometer and gyroscope of a smartphone. IEEE J. Biomed. Health Inform. 22, 108–118 (2017).
MedlineGoogle Scholar
23. Chan PH, Wong CK, Poh YC et al. Diagnostic performance of a smartphone-based photoplethysmographic application for atrial fibrillation screening in a primary care setting. J. Am. Heart Assoc. 5(7), pii: e003428 (2016).
Google Scholar
24. Turakhia MP, Ullal AJ, Hoang DD et al. Feasibility of extended ambulatory electrocardiogram monitoring to identify silent atrial fibrillation in high-risk patients: the Screening Study for Undiagnosed Atrial Fibrillation (STUDY-AF). Clin. Cardiol. 38(5), 285–292 (2015).
MedlineGoogle Scholar
25. Dalen JE, Alpert JS. Silent atrial fibrillation and cryptogenic strokes. Am. J. Med. 130(3), 264–267 (2017).
MedlineGoogle Scholar
26. Hart RG, Sharma M, Mundl H et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N. Engl. J. Med. 378(23), 2191–2201 (2018).
Medline CASGoogle Scholar
27. Diener HC, Sacco RL, Easton JD et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N. Engl. J. Med. 380(20), 1906–1917 (2019).
Medline CASGoogle Scholar
28. Hohnloser SH, Pajitnev D, Pogue J et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J. Am. Coll. Cardiol. 50(22), 2156–2161 (2007).
Medline CASGoogle Scholar
29. Hahne K, Monnig G, Samol A. Atrial fibrillation and silent stroke: links, risks, and challenges. Vasc. Health Risk Manag. 12, 65–74 (2016).
MedlineGoogle Scholar
30. Gaita F, Corsinovi L, Anselmino M et al. Prevalence of silent cerebral ischemia in paroxysmal and persistent atrial fibrillation and correlation with cognitive function. J. Am. Coll. Cardiol. 62(21), 1990–1997 (2013).
MedlineGoogle Scholar
31. Dilaveris PE, Kennedy HL. Silent atrial fibrillation: epidemiology, diagnosis, and clinical impact. Clin. Cardiol. 40(6), 413–418 (2017).
MedlineGoogle Scholar
32. Rizos T, Horstmann S, Dittgen F et al. Preexisting heart disease underlies newly diagnosed atrial fibrillation after acute ischemic stroke. Stroke 47(2), 336–341 (2016).
MedlineGoogle Scholar
33. Yang XM, Rao ZZ, Gu HQ et al. Atrial fibrillation known before or detected after stroke share similar risk of ischemic stroke recurrence and death. Stroke 50(5), 1124–1129 (2019).
MedlineGoogle Scholar
34. Acampa M, Lazzerini PE, Martini G. How to identify patients at risk of silent atrial fibrillation after cryptogenic stroke: potential role of P wave dispersion. J. Stroke 19(2), 239–241 (2017).
MedlineGoogle Scholar
35. Acampa M, Lazzerini PE, Guideri F et al. Electrocardiographic predictors of silent atrial fibrillation in cryptogenic stroke. Heart Lung Circ. 28(11), 1664–1669 (2019).
MedlineGoogle Scholar
36. Sposato LA, Cipriano LE, Saposnik G, Ruiz Vargas E, Riccio PM, Hachinski V. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol. 14(4), 377–387 (2015).
MedlineGoogle Scholar
37. Kernan WN, Ovbiagele B, Black HR et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 45(7), 2160–2236 (2014).
MedlineGoogle Scholar
38. Brachmann J, Morillo CA, Sanna T et al. Uncovering atrial fibrillation beyond short-term monitoring in cryptogenic stroke patients: three-year results from the cryptogenic stroke and underlying atrial fibrillation trial. Circ. Arrhythm. Electrophysiol. 9(1), e003333 (2016). •• Crystal-AF trial comparing implantable loop recorders to long-lasting external Holters in AF screening after stroke.
MedlineGoogle Scholar
39. Sanna T, Diener HC, Passman RS et al. Cryptogenic stroke and underlying atrial fibrillation. N. Engl. J. Med. 370(26), 2478–2486 (2014).
Medline CASGoogle Scholar
40. Tanislav C, Adarkwah CC, Jakob L, Kostev K. Increased risk for cancer after stroke at a young age: etiological relevance or incidental finding? J. Cancer Res. Clin. Oncol. 145(12), 3047–3054 (2019).
MedlineGoogle Scholar
41. Strongman H, Gadd S, Matthews A et al. Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases. Lancet 394(10203), 1041–1054 (2019).
MedlineGoogle Scholar
42. Rochette L, Guenancia C, Gudjoncik A et al. Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms. Trends Pharmacol. Sci. 36(6), 326–348 (2015).
Medline CASGoogle Scholar
43. Meierhenrich R, Steinhilber E, Eggermann C et al. Incidence and prognostic impact of new-onset atrial fibrillation in patients with septic shock: a prospective observational study. Crit. Care 14(3), R108 (2010).
MedlineGoogle Scholar
44. Walkey AJ, Greiner MA, Heckbert SR et al. Atrial fibrillation among Medicare beneficiaries hospitalized with sepsis: incidence and risk factors. Am. Heart J. 165(6), 949–955 e943 (2013).
MedlineGoogle Scholar
45. Walkey AJ, Hammill BG, Curtis LH, Benjamin EJ. Long-term outcomes following development of new-onset atrial fibrillation during sepsis. Chest 146(5), 1187–1195 (2014).
MedlineGoogle Scholar
46. Walkey AJ, Quinn EK, Winter MR, Mcmanus DD, Benjamin EJ. Practice patterns and outcomes associated with use of anticoagulation among patients with atrial fibrillation during sepsis. JAMA Cardiol. 1(6), 682–690 (2016).
MedlineGoogle Scholar
47. Walkey AJ, Wiener RS, Ghobrial JM, Curtis LH, Benjamin EJ. Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis. JAMA 306(20), 2248–2254 (2011).
Medline CASGoogle Scholar
48. Guenancia C, Stamboul K, Garnier F et al. Obesity and new-onset atrial fibrillation in acute myocardial infarction: a gender specific risk factor. Int. J. Cardiol. 176(3), 1039–1041 (2014).
MedlineGoogle Scholar
49. Stamboul K, Lorin J, Lorgis L et al. Atrial fibrillation is associated with a marker of endothelial function and oxidative stress in patients with acute myocardial infarction. PLoS ONE 10(7), e0131439 (2015).
MedlineGoogle Scholar
50. Stamboul K, Zeller M, Fauchier L et al. Incidence and prognostic significance of silent atrial fibrillation in acute myocardial infarction. Int. J. Cardiol. 174(3), 611–617 (2014).
MedlineGoogle Scholar
51. Stamboul K, Zeller M, Fauchier L et al. Prognosis of silent atrial fibrillation after acute myocardial infarction at 1-year follow-up. Heart 101(11), 864–869 (2015).
MedlineGoogle Scholar
52. Guenancia C, Toucas C, Fauchier L et al. High rate of recurrence at long-term follow-up after new-onset atrial fibrillation during acute myocardial infarction. Europace 20(12), e179–e188 (2018).
MedlineGoogle Scholar
53. Lopes RD, Alings M, Connolly SJ et al. Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. Am. Heart J. 189, 137–145 (2017).
MedlineGoogle Scholar
54. Kalman JM, Sanders P, Rosso R, Calkins H. Should we perform catheter ablation for asymptomatic atrial fibrillation? Circulation 136(5), 490–499 (2017).
MedlineGoogle Scholar

Vol. 16, No. 2

Metrics

Downloaded 158 times

History

Received 14 October 2019

Accepted 11 February 2020

Published online 3 March 2020

Published in print March 2020

Information

Keywords

Acknowledgments

The authors thank Suzanne Rankin for English revision of the paper.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download

Silent atrial fibrillation: clinical management and perspectives

Abstract

References